Technical Data
G8601-13M
GPR109B (G-protein Coupled Receptor 109B, G-protein Coupled Receptor HM74, G-protein Coupled Receptor HM74B, Niacin Receptor 2, Nicotinic Acid Receptor 2, HM74B, NIACR2)
Description:
GPR109B is a membrane protein belonging to family 1 of G protein-coupled receptor (GPCR) is homologous to GPR109A. GPR109B, a potential 7 transmembrane-spanning receptor, shows a significant homology to B2 bradykinin receptor and to thrombin receptor. GPR109B mediates the anti-lipolytic and lipid-lowering effect of nicotinic acid by acting as a nicotinic acid receptor and results in a G protein-mediated decrease in cAMP levels and hence are promising targets for future pharmacotherapy. It is known to show highest expression in spleen followed by lymphocytes and adipose tissue.

Applications:
Suitable for use in Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 0.5-2ug/ml
Immunohistochemistry (paraffin): 10ug/ml
Optimal dilutions to be determined by the researcher.

Positive Control:
Human liver lysate.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanRabbit
Concentration:
~0.5mg/ml
Immunogen:
Synthetic peptide corresponding to aa1-50 of human GPR109B.
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in PBS, 0.2% gelatin, 0.05% sodium azide.
Specificity:
Recognizes human GPR109B. Species Crossreactivity: chimpanzee. Species sequence homology: mouse and rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Tunaru, S. et al. Nat. Med. 9:352-355 (2003). 2. Nomura, H. et al. Int. Immunol. 5:1239-1249 (1993). 3. Wise, A. et al. J. Biol. Chem. 278:9869-9874 (2003).